These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26858577)

  • 1. Pituitary pars intermedia dysfunction (equine Cushing's disease) in a Thoroughbred stallion: a single report.
    Hatazoe T; Kawaguchi H; Hobo S; Misumi K
    J Equine Sci; 2015; 26(4):125-8. PubMed ID: 26858577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pituitary pars intermedia dysfunction (Equine Cushing's disease) in an onager (Equus hemionus onager).
    Peel AJ; Bouts T; Flach E; Rivers S; Routh A
    J Zoo Wildl Med; 2009 Dec; 40(4):773-80. PubMed ID: 20063825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PITUITARY PARS INTERMEDIA DYSFUNCTION (EQUINE CUSHING'S DISEASE) IN NONDOMESTIC EQUIDS AT MARWELL WILDLIFE: A CASE SERIES. ONE CHAPMAN'S ZEBRA ( EQUUS QUAGGA CHAPMANI) AND FIVE PRZEWALSKI's HORSES ( EQUUS FERUS PRZEWALSKII).
    Shotton JCR; Justice WSM; Salguero FJ; Stevens A; Bacci B
    J Zoo Wildl Med; 2018 Jun; 49(2):404-411. PubMed ID: 29900762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.
    Fortin JS; Benskey MJ; Lookingland KJ; Patterson JS; Howey EB; Goudreau JL; Schott HC
    BMC Vet Res; 2020 Sep; 16(1):356. PubMed ID: 32977825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.
    Rendle DI; Doran G; Ireland J; Edwards S
    Domest Anim Endocrinol; 2019 Jul; 68():135-141. PubMed ID: 31082785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis.
    Donaldson MT; Jorgensen AJ; Beech J
    J Am Vet Med Assoc; 2004 Apr; 224(7):1123-7. PubMed ID: 15074858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equine pituitary pars intermedia dysfunction: current perspectives on diagnosis and management.
    Spelta CW
    Vet Med (Auckl); 2015; 6():293-300. PubMed ID: 30101114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of pituitary pars intermedia dysfunction in practice: A clinical audit.
    Steel NL; Ireland JL; McGowan CM
    Vet J; 2022 Nov; 289():105899. PubMed ID: 36162625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses.
    McGowan TW; Pinchbeck GP; McGowan CM
    Equine Vet J; 2013 Jan; 45(1):74-9. PubMed ID: 22594955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-melanocyte stimulating hormone release in response to thyrotropin releasing hormone in healthy horses, horses with pituitary pars intermedia dysfunction and equine pars intermedia explants.
    McFarlane D; Beech J; Cribb A
    Domest Anim Endocrinol; 2006 May; 30(4):276-88. PubMed ID: 16115743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between endogenous plasma adrenocorticotropic hormone concentration and reproductive performance in Thoroughbred broodmares.
    Tsuchiya T; Noda R; Ikeda H; Maeda M; Sato F
    J Vet Intern Med; 2021 Jul; 35(4):2002-2008. PubMed ID: 34028083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Equine pituitary pars intermedia dysfunction.
    McFarlane D
    Vet Clin North Am Equine Pract; 2011 Apr; 27(1):93-113. PubMed ID: 21392656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease).
    Donaldson MT; LaMonte BH; Morresey P; Smith G; Beech J
    J Vet Intern Med; 2002; 16(6):742-6. PubMed ID: 12465775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of rhythms of secretion and repeatability of plasma adrenocorticotropic hormone concentrations in healthy horses and horses with pituitary pars intermedia dysfunction.
    Rendle DI; Litchfield E; Heller J; Hughes KJ
    Equine Vet J; 2014 Jan; 46(1):113-7. PubMed ID: 23742059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case series of equine pituitary pars intermedia dysfunction in a tropical climate.
    Spelta CW; Axon JE
    Aust Vet J; 2012 Nov; 90(11):451-6. PubMed ID: 23106327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perianesthetic development of diaphragmatic hernia in a horse with equine pituitary pars intermedia dysfunction (PPID).
    Shepard MK; Lee WL; Eggleston RB
    Can Vet J; 2015 Jan; 56(1):48-52. PubMed ID: 25565714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proopiolipomelanocortin peptides in normal pituitary, pituitary tumor, and plasma of normal and Cushing's horses.
    Wilson MG; Nicholson WE; Holscher MA; Sherrell BJ; Mount CD; Orth DN
    Endocrinology; 1982 Mar; 110(3):941-54. PubMed ID: 6276164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamellar pathology in horses with pituitary pars intermedia dysfunction.
    Karikoski NP; Patterson-Kane JC; Singer ER; McFarlane D; McGowan CM
    Equine Vet J; 2016 Jul; 48(4):472-8. PubMed ID: 25869529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Equine Cushing syndrome (ECS). Case report, review of its diagnosis and therapy and substantial differences from Cushing syndrome in dogs].
    Fey K; Jonigkeit E; Moritz A
    Tierarztl Prax Ausg G Grosstiere Nutztiere; 1998 Feb; 26(1):41-7. PubMed ID: 9626747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pituitary pars intermedia dysfunction: equine Cushing's disease.
    Schott HC
    Vet Clin North Am Equine Pract; 2002 Aug; 18(2):237-70. PubMed ID: 15635907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.